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 Fungi have emerged worldwide as increasingly frequent causes of healthcare-
associated infections. Invasive fungal infections can be life-threatening. However, the 
number of antifungal agents available and their use in therapy is very limited. Recently, 
a new family of specific fungal cell wall synthesis inhibitors has emerged as an 
alternative antifungal therapy and is gaining increasing relevance yearly. The cell wall 
is a multilayer dynamic structure, essential to the integrity and shape of the fungal cell, 
whose function is to counteract the osmotic forces that could otherwise produce fungal 
cell lysis. The cell wall is absent in nonfungal cells, therefore representing a useful 
target in discovering selective drugs for the treatment of fungal infections without 
causing toxicity in the host. Although fungi exhibit a considerable diversity in their cell 
wall structure, all present β(1,3)-, β(1,6)- and α(1,3)-glucans, chitin, and mannoproteins 
as their major cell wall components. Three different cell wall synthesis inhibitors of the 
lipopeptide family of echinocandins, named caspofungin, micafungin and 
anidulafungin, are commercially-available and new classes of cell wall synthesis 
inhibitors are emerging. This review provides an overview of what is so far known 
about the different classes of cell wall-affecting antifungal agents and their mechanism 
of action, offering new alternatives with clinical potential. 
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 Invasive fungal infections are devastating. Despite the progressive development 
of new antifungal therapies, the mortality rates for invasive mycoses often reach the 
50% (Lai et al., 2008, Park et al., 2009). Although fungal infections affect to individuals 
with intact immune systems, invasive aspergillosis and mucormycosis continue 
increasing in parallel with the growth of immunocompromised patients (Brown et al., 
2012b). Improved diagnostics, new epidemiological analysis and new antifungals 
available have changed the field of medical mycology in the past few decades 
(Ostrosky-Zeichner et al., 2010).  
 
 The high phylogenetic similarity between fungi and humans makes that 
relatively few differential targets, can be used for antifungal drug development. Fungi 
originate a huge collection of extracellular enzymes and secondary metabolites to 
counteract and digest other fungi and microorganisms from their environment; thus 
many antimicrobial agents have been isolated from fungi themselves. The best example 
is penicillin, which was isolated from Penicillium notatum (now Penicillium 
chrysogenum). Similarly, the echinocandins, a class of antifungal compounds now in 
extensive clinical use, are semisynthetic derivatives of fungal-produced cyclic 
hexapeptides (Denning and Hope, 2010, Chain et al., 1993).  
 
 Presently, five classes of antifungal drugs are used for the treatment of fungal 
infections in humans: allylamines, azoles, echinocandins, polyenes and pyrimidine 
analogues. These drugs show some limitations, such as the nephrotoxicity of 
amphotericin B and the emerging resistance to the azoles (Cartledge et al., 1997), 
despite several improvements, such as new lipid formulations of polyenes with lower 
toxicity and new triazoles with a wider spectrum of action (Granier, 2000). The 
development of new antifungal agents, preferably naturally occurring with novel 
mechanisms of action, is an urgent medical need (Vicente et al., 2003). In the last years, 
new synthetic and semi-synthetic inhibitors of the cell wall synthesis have emerged 
(Hector and Bierer, 2011), being effective against the main infectious agents of life-
threatening mycoses. In addition to the more traditional classes of cell wall synthesis 
inhibitors, this chapter focuses and reviews some of the new and more promising 
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classes of such compounds, and their mechanism of action, concentrating on the most 
promising candidates that are nearing or currently in clinical development. 
 
2. Sites of action of the antifungal agents 
 
 The sites of action of all the antifungal agents used in clinic therapy are 
summarized in figure 1, showing the extensive range of antifungal targets that already 
exists. Nevertheless, the classes of agents that can be used against life-threatening 
mycoses are heavily focused, directly or indirectly, on the pathogen cell envelope (cell 
wall and plasma membrane), and particularly on the membrane complex (1,3)-glucan 
synthase (GS), in charge of the biosynthesis of the cell wall (1,3)-glucan; and on the 
membrane ergosterol and its biosynthesis (Chapter 8 of this book). Targets elsewhere in 
the cell would therefore be a welcome advance for systemically bioavailable antifungal 
agents. The introduction of the echinocandins (anidulafungin, caspofungin and 
micafungin are the only new drugs licensed within the last 10 years) and the third-
generation triazoles (voriconazole and posaconazole), in particular, have enhanced 
therapeutic options for many fungal infections (Brown et al., 2012a, Ostrosky-Zeichner 
et al., 2010). 
 
3. The fungal cell wall 
 
 The extracellular fungal wall is responsible for the cell shape, provides 
mechanical protection, and supports the internal osmotic pressure of fungal cells. In 
addition, its rigid structure is useful for penetration into and colonization of insoluble 
substrates. This structure is not simply a rigid exoskeleton, but has the flexibility 
required for allowing cell growth, cell division and the formation of numerous cell types 
during the fungal life cycle. The functional equivalent of the fungal cell wall in animal 
cells is denominated extracellular matrix, but its composition and osmotic and structural 
properties are totally different from those of the cell wall. Therefore, although both 
structures are functionally equivalent, their differences permit that the cell wall-
affecting antifungals specifically inhibit the fungal cell wall synthesis without affecting 
the extracellular matrix of animal cells (Durán and Pérez, 2004, Free, 2013, Latge, 
2007, Lesage and Bussey, 2006, Levin, 2011, Lu et al., 2012, White and Bednarek, 
2003, Oh et al., 2012)  
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 The cell wall is also critical for biofilm formation, a process that many fungi 
participate in, and which is an important ecological niche for a variety of fungi. For 
fungal pathogenicity, the cell wall is the surface of interaction between pathogen and 
host, being critical for its virulence and pathogenicity, providing both adhesive 
properties critical for invasion of host tissue and protection against the host defense 
mechanisms. Alterations of cell wall structure have a deep impact on the growth, 
morphology and integrity of the fungal cell, often leading to lysis by plasma membrane 
breaking and release of cytoplasm content. Given the essential role of the cell wall in 
fungal survival, this structure has long been considered an excellent target for antifungal 
agents (Free, 2013).   
 
 To build their walls, the fungal cells must synthesize the wall components in or 
export them across the plasma membrane, and assemble them outside the cell (Figure 
2). The wall is composed basically of polysaccharides (70-90%) and glycoproteins (10-
30%). Although composition varies among fungal species, most walls have a common 
structure (Latge, 2007). When observed by transmission electron microscopy, the cell 
walls show two electron dense external layers rich in glycoproteins and an internal layer 
more transparent to the electrons, which mainly contains fibrillar polysaccharides 
(Figure 2).  
 
 The main fungal wall fibrillar components are: glucose homopolymers, β(1,3)-
glucan with different percentages of β(1,6) branches depending on the fungal species; 
chitin, a β(1,4)-N-acetylglucosamine polymer; and α(1,3)-glucan. Chitin accounts for 
only 1–2% of the yeasts wall (Cabib et al., 1988, Lesage and Bussey, 2006), whereas 
filamentous fungi, such as Neurospora or Aspergillus, contain 10–20% of chitin in their 
walls (Latge, 2007). In both yeasts and filamentous fungi, chitin forms microfibrils by 
interchain hydrogen bonding, which have enormous tensile strength and significantly 
contribute to the overall integrity of the cell wall (Cabib and Kang, 1987). Similarly, 
α(1,3)-glucan is essential for the adhesion strength of the cell wall components (Cortés 
et al., 2012). 
 
 The wall polysaccharides are formed at the plasma membrane by synthase 
enzymes and extruded to the periplasmic space (Figure 2), where they bind to each 
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other. The linkages among the different components, which results in a tightly linked 
network, are generated by transglycosylation (Cabib et al., 2007, Cabib et al., 2008) and 
are responsible for the mechanical strength of the cell wall (Cabib and Kang, 1987, 
Kapteyn et al., 1997, Kollar et al., 1995, Kollar et al., 1997).   
 
4. Cell wall components  
 
4.1. (1,3)-glucan  
  
 (1,3)-glucan is the main structural polysaccharide of the wall and represents 50-
60% of the total cell wall polysaccharides. Most of glucan polymers are composed of 
glucose units linked with (1,3) bonds (65-90%), although there are also some (1,6), 
(1,4), α(1,3) and α(1,4) glucans. The (1,3)-glucan chains display a coiled spring-like 
structure that confers elasticity and tensile strength to the cell wall. Usually the (1,3)-
glucan is formed by a main backbone of (1,3)-glucan and by (1,6)-linked side chains 
(Figure 1, upper panel). In these linear chains of (1,3)-glucan, new glucose units bind 
forming β(1,6) branches in variable proportion depending on the organism, from almost 
linear to highly branched. Then, the β(1,6)-branched (1,3)-glucan can bind to other 
glucans, to chitin or to glycoproteins, providing a great mechanical resistance to the 
wall, which is essential to maintain the fungal cell integrity (Klis et al., 2002, Kollar et 
al., 1995, Kollar et al., 1997, Lesage and Bussey, 2006).  
 
4.1.1. (1,3)-glucan synthase (GS) complex  
 
 (1,3)-glucan chains are synthesized by the enzyme complex (1,3)-glucan 
synthase (GS), which is located in the plasma membrane. The echinocandins interfere 
with the production of (1,3)-glucan and target the GS directly (Douglas, 2001). This 
family of enzymes use uridine-diphospho-glucose (UDP-Glc) as substrate and catalyze 
the reaction 2n UDP-Glc→ [Glc--1,3-Glc]n in the presence of GTP, resulting in the 
formation of linear glucan chains composed of approximately, 1,500 (1,3)-bound 
glucose residues (Figure 1, upper panel) (Cabib and Kang, 1987). The GS complex is 
composed by at least two subunits, which were identified by detergent and high ionic 
strength extraction from the plasma membrane, followed by an in vitro assay for GS 
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activity. Under these conditions, the GS complex was separated into a membrane bound 
and a cytosolic fraction, containing the catalytic and regulatory GTP-binding subunits, 
respectively (Kang and Cabib, 1986): 
 
4.1.1.1. Catalytic subunit  
 
 The genes coding for the putative GS catalytic subunit were initially identified in 
S. cerevisiae and named FKS1 and GSC2/FKS2 (Douglas et al., 1994b, Mazur et al., 
1995). FKS1 (for FK506 sensitive) was initially cloned by complementation of a mutant 
hypersensitive to the calcineurin inhibitor FK506 (Parent et al., 1993). The discovery 
that ETG1 and PBR1 (whose mutants are resistant to GS inhibitors), CND1 (the cnd1 
mutant requires a functional calcineurin pathway), and CWH53 (required for resistance 
to calcofluor white) are all identical to FKS1, established the link between Fks1 and the 
cell wall (Castro et al., 1995, Douglas et al., 1994a, El-Sherbeini and Clemas, 1995, 
Garrett-Engele et al., 1995, Ram et al., 1995). FKS1 mutants show decreased GS 
activity, and Fks1 is enriched in membrane fractions enriched in GS activity, suggesting 
that Fks1 could be a GS catalytic subunit (Douglas et al., 1994a, Inoue et al., 1995).  
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 Fks2/Gsc2 is 88% identical to Fks1 and presents similar topology and domain 
organization to that of Fks1. Fks1 and Fks2 are thought to be alternative subunits of the 
GS complex, with a double fks1 fks2 mutant being nonviable. This synthetic lethality 
and the finding that membrane extracts from cells expressing only FKS2, show a GS 
activity that can be depleted after treatment with anti-Fks2 antibodies, suggested that 
Fks2 is involved in (1,3)-glucan synthesis (Inoue et al., 1999, Mazur et al., 1995). 
 
 FKS1 and FKS2 show differential expression patterns. FKS1 transcription is 
cell-cycle regulated, and linked to cell wall remodeling. FKS2 transcription is 
calcineurin-dependent (Kurtz and Rex, 2001). FKS1 is expressed during mitotic growth, 
in agreement with its proposed function as the major GS subunit. fks1 cells show 
reduced GS activity and altered cell wall composition, with decreased (1,3)- and 
(1,6)-glucan levels, and increased chitin and mannan levels (Dijkgraaf et al., 2002, 
Douglas et al., 1994a, Lesage and Bussey, 2006). In contrast, during vegetative growth 
the fks2 mutant does not display cell wall or cell growth defects. However, during 
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sexual differentiation the fks2 cells are impaired in spore wall assembly. The strength 
of the phenotypes observed in fks1 compared to those observed in fks2 cells, suggest 
that Fks1 is the main responsible for GS activity and (1,3)-glucan synthesis during 
vegetative growth, while Fks2 would function under more stressful conditions (Lesage 
and Bussey, 2006). The S. cerevisiae FKS family has a third member, FKS3, whose 
product is required for sporulation (Deutschbauer et al., 2002, Ishihara et al., 2007). 
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 The Fks protein family of GS is very well conserved in fungi and plants, and are 
large multispan membrane proteins with a hydrophilic central region (Johnson and 
Edlind, 2012). Orthologs of these genes have been described in the main fungal genera, 
encoding proteins with a high degree of identity ranging from 56% (Cryptococcus 
neoformans) to 83% (Candida glabrata) (Latge, 2007, Lesage and Bussey, 2006, Pérez 
and Ribas, 2004, Cortés et al., 2002).  
 
The fission yeast Schizosaccharomyces pombe has provided an appealing model 
for studies addressing cell wall synthesis and morphogenesis. The cell wall of S. pombe 
has no detectable chitin (Durán and Pérez, 2004), but it contains three different essential 
(1,3)-glucans as follows: a (1,6)-branched (1,3)-glucan, which is the major 
contributor to the cell wall structure; a minor linear (1,3)-glucan, concentrated in the 
primary septum, with residual amounts in the cell wall; and a minor branched (1,6)-
glucan (Cortés et al., 2007, Humbel et al., 2001). S. pombe contains four genes, bgs1+ to 
bgs4+, which encode four different GS catalytic subunits of the Fks protein family, and 
three of them (Bgs1, 3 and 4) are essential during vegetative growth. Differently to what 
has been described for S. cerevisiae and some other fungi, where Fks1 and Fks2 have 
been shown to have redundant functions (see above), S. pombe GS catalytic subunits 
display differential essential non-overlapping functions in the assembly and the 
transport of different (1,3)-glucans during polarized cell wall growth, septum synthesis 
and ascospore wall assembly. The different essential functions of Bgs proteins in cell 
wall synthesis and morphogenesis make them good targets for the search and study of 
new improved antifungal drugs that specifically inhibit (1,3)-glucan synthesis. bgs1+ 
was initially cloned by phenotype complementation of a mutant that displays 
hypersensitivity to Cyclosporin A as well as Papulacandin B, and the encoded protein 
Bgs1 is responsible for the synthesis of the linear (1,3)-glucan and primary septum 
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+ was identified as a 
suppressor of a mutant that shows hypersensitivity to echinocandin. Bgs3 is essential, 
although its function remains unknown (Carnero et al., 2000, Liu et al., 2000, Martín et 
al., 2000). bgs4+ encodes the only subunit that has been shown to form part of the GS 
enzyme. It is responsible for most of the cell wall (1,3)-glucan synthesis and in vitro 
GS activity, and it is essential for the maintenance of cell integrity during cell growth 
and mainly septum synthesis. To date the only identified mutants of S. pombe that 
display reduced levels of -glucan and GS activity, or resistance to specific GS 
inhibitors, are due to point mutations in the Bgs4 sequence (Castro et al., 1995, Cortés et 
al., 2005, Martins et al., 2011, Ribas et al., 1991b, Ribas et al., 1991a). 
 
 The presence of multiple FKS/bgs genes in some fungi might be the result of the 
ancient and selective retention of duplicated genes through increased fitness conferred 
by their specialized application of GS functions (Lesage and Bussey, 2006). This 
complexity is also found in plants, where the Fks/Bgs protein family of GS is also 
present. Plant GS synthesize a (1,3)-glucan polymer denominated  callose. Although 
(1,3)-glucan is less abundant in plants than in fungi, the number of GS genes is much 
higher in plants than in fungi. Thus, Arabidopsis thaliana or Oryza sativa contain 12–18 
callose synthase genes whereas the highest number of genes in fungi are the 4 bgs genes 
identified in S. pombe. Plant callose is involved in pollen development (primary and 
secondary cell wall of the pollen, germination pore and pollen tube) as well as wound 
repair after injury or disease. Similarly to S. pombe (1,3)-glucans, all steps in which 
callose participates should involve different callose synthase genes, which would 
explain the existence of multiple callose synthase genes in plants. Despite plant and 
fungi belong to different kingdoms, plant and fungal GS display high sequence identity 
(Cortés et al., 2007, Latge, 2007, Verma, 2001, Verma and Hong, 2001).  
 
 The GS catalytic subunit is thought to extrude (1,3)-glucan chains produced on 
the periplasmic face of the plasma membrane for incorporation into the wall. Although 
the GS enzyme has never been purified to homogeneity, the central hydrophilic domain 
of partially purified Neurospora crassa Fks protein was shown to crosslink to azido-
UDP-glucose, supporting the conclusion that this protein is the catalytic subunit 
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(Schimoler-O'Rourke et al., 2003). Purification of the complete and active GS catalytic 
subunits will require new advances in our knowledge of enzymatically active integral 
membrane protein complexes (Lesage and Bussey, 2006, Levin, 2011). 
 
4.1.1.2. The regulatory subunit Rho1  
 
 Besides the catalytic subunit, fungal GS require GTP-bound Rho1 GTPase for 
their activity. Essential Rho1 is the prototype of small G proteins, which in their active 
GTP-bound state bind and activate their effectors. After synthesis in the endoplasmic 
reticulum, Rho1 is geranylgeranylated, allowing its anchoring to the membrane through 
a C-terminal prenylated tail, which is required for Rho1-membrane association and 
activation of GS activity (Arellano et al., 1998, Díaz et al., 1993, Inoue et al., 1999). 
Different biochemical and genetic approaches have pointed out to Rho1 GTPase as a 
regulator of GS: (i) Rho1 colocalizes and copurifies with Fks1 and cofractionates with 
GS activity, (ii) thermosensitive rho1 mutations cause thermolabile GS activity, (iii) a 
hyperactive rho1 allele shows a GTP-independent GS (iv) overproduction of Rho1 is 
able to partly suppress the GS deficiency of a geranylgeranyltransferase type I mutant 
(Arellano et al., 1996, Drgonova et al., 1996, Mazur and Baginsky, 1996, Qadota et al., 
1996, Kondoh et al., 1997). Geranylgeranylated Rho1p is transported to the plasma 
membrane, where is thought to be activated by its GDP/GTP exchange factors. This 
localized activation on the plasma membrane is required for proper cell wall (1,3)-
glucan synthesis (Abe et al., 2003, Díaz et al., 1993, Inoue et al., 1999, Perez and 
Rincon, 2010). Although the Fks family members are well established as Rho1 
effectors, the interaction domains between the GS catalytic and regulatory subunits and 
the basis for Rho1 activation on the GS catalytic subunits remain unknown (Lesage and 
Bussey, 2006). 
 
4.2. (1,6)-Glucan 
 
 In addition to (1,3)-glucan, most of fungal walls contain a second -linked 
glucan, the (1,6)-glucan. This polymer is shorter than (1,3)-glucan, it does not form a 
fibrillar structure, and acts as a flexible glue by forming covalent cross-links to (1,3)-
glucan, chitin, and glycoproteins (Kollar et al., 1997). Comparative studies show the 
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variability of (1,6)-glucan structures among fungi, with the most highly branched S. 
pombe diglucan, likely a variant of the (1,6)-glucan found in S. cerevisiae and C. 
albicans (Lesage and Bussey, 2006). To date, most of the genes implicated in the 
synthesis of (1,6)-glucan have been identified in S. cerevisiae. The site of (1,6)-
glucan synthesis has been controversial for many years. Defects in (1,6)-glucan 
synthesis are observed in mutations of genes as CWH41, ROT2, KRE5 and CNE1, 
encoding glucosidases I and II and UDP-glucose: glycoprotein glucosyltransferase- 
[UGGT]- and calnexin-related proteins, respectively. These proteins are involved in 
different steps of the secretory pathway (Page et al., 2003, Lesage and Bussey, 2006, 
Shahinian and Bussey, 2000), suggesting that biosynthesis of this polymer could start in 
the endoplasmic reticulum. In S. pombe, an immuno-electron microscopy analysis 
showed particles of (1,6)-glucan associated to the Golgi apparatus (Humbel et al., 
2001), suggesting that biosynthesis of this polymer progresses in the Golgi, and is 
completed at the cell surface. Indeed, S. cerevisiae glucosyl hydrolases (or 
transglucosylases) Kre6 and Skn1 are critical for (1,6)-glucan synthesis and reside in 
the Golgi (Roemer and Bussey, 1991, Roemer et al., 1994). However, a late secretory 
pathway mutant displayed (1,6)-glucan exclusively accumulated in the cell surface, 
indicating that a block of the secretion does not cause an accumulation of intracellular 
(1,6)-glucan (Montijn et al., 1999), suggesting that (1,6)-glucan, like (1,3)-glucan, 
may be synthesized at the plasma membrane. An in vitro assay for (1,6)-glucan 
synthesis using specific antibodies against (1,6)-glucan has been developed (Vink et 
al., 2004). This assay requires membrane extracts, UDP-glucose and GTP and shows 
enhanced activity in cells overexpressing Rho1, suggesting that the (1,6)-glucan could 
be synthesized at the sites of polarized cell growth where Rho1 is detected. Besides, the 
use of membrane extracts from defective (1,6)-glucan mutants correlated the decreased 
in vitro (1,6)-glucan synthase activity with the low levels of in vivo cell wall (1,6)-
glucan (Levin, 2011, Vink et al., 2004).  
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4.3. Chitin  
 
 Chitin is a β(1,4)-linked homopolymer of N-acetylglucosamine that forms 
microfibrils stabilized by hydrogen bonds. This polymer is present in the walls of all 
fungi studied to date with the exception of S. pombe. Chitin represents 1-2% of the yeast 
 11
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
cell wall whereas in filamentous fungi, it can reach up to 10-20% (Latge, 2007). Chitin 
is synthesized from N-acetylglucosamine units by the enzyme chitin synthase (CS) that 
deposits microfibrils of chitin outside of the plasma membrane. This family of enzymes 
use uridine-diphosphate-N-acetylglucosamine (UDP-GlcNAc) as substrate and catalyze 
the reaction 2n UDP-GlcNAc → [GlcNAc--1,4-GlcNAc]n. Chitin biosynthesis is best 
understood in S. cerevisiae, where it has been broadly studied. Three CS activities (CSI, 
CSII, and CSIII) have been identified in membrane extracts, and the corresponding 
catalytic subunits have been identified as Chs1, Chs2 and Chs3, respectively. The three 
Chs proteins are integral membrane proteins, each one responsible for the synthesis of a 
chitin (Cabib et al., 2001) at different times and places during cell growth. Chs1 acts as 
a repair enzyme during cell separation; Chs2 is responsible for synthesis of the primary 
septum chitin; and Chs3 synthesizes most of the cell wall chitin and is responsible for 
the increase in chitin synthesis observed when the cell wall is stress-affected (Roncero 
and Sanchez, 2010, Schmidt et al., 2002). The number of CS genes varies from 1 to 20 
according to the fungal species. The large family of CS enzymes fall into seven classes 
according on the evolution of their amino acid sequences (Roncero, 2002). The 
multiplicity of enzymes suggests that they have redundant roles in chitin synthesis and 
makes it difficult to find functional significance to the different classes (Lenardon et al., 
2010). 
 
4.4. α(1,3)-glucan 
 
 Many fungi contain α(1,3)(1,4)-glucan in their cell wall. However, the 
corresponding in vitro α(1,3)-glucan synthase activity has not been detected yet. A 
putative catalytic subunit was first described in S. pombe (Cortés et al., 2012, 
Hochstenbach et al., 1998, Katayama et al., 1999). Ags1/Mok1 is a multidomain 
integral membrane protein with a predicted cytoplasmic synthase domain, multiple 
transmembrane domains and an extracellular transglycosylase domain. The cytoplasmic 
synthase domain would add glucose residues to the non-reducing end of an α(1,3)-
glucan glucan chain. Interestingly, the large extracellular N-terminal region presents 
homology to transglucanases, which could function in cross-linking newly synthesized 
α(1,3)-glucan to other cell wall components (Grun et al., 2005, Vos et al., 2007). The 
α(1,3)-glucan synthesized by Ags1/Mok1 is vital for cell integrity during polar growth 
and mainly cell separation, and to maintain the adhesion between cell wall components, 
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primarily in the septum during cell separation (Cortés et al., 2012). S. pombe contains 
five genes coding for Ags/Mok proteins, and genomes of other fungi, including several 
pathogens in which the cell wall α-glucan accounts for around 35% of the total wall 
polysaccharides, present sequences of predicted proteins homologous to the Ags/Mok 
family (Edwards et al., 2011, García et al., 2006, Henry et al., 2011). 
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4.5. Glycoproteins 
  
 Glycoproteins represent 30-50% of the dry weight of the walls of S. cerevisiae 
or Candida, and around 15-20% of the dry weight of S. pombe and filamentous fungi 
walls. The glycoproteins present in the cell wall are expansively modified with both N- 
and O-linked carbohydrates, predominantly or exclusively formed by mannose residues 
known as mannan. In some cases, the mannan backbone presents single residues or side 
chains of different sugars, galactomannan, rhamnomannan, glucogalactomannan, 
rhamnogalactomannan, etc. (Bowman and Free, 2006, Leal et al., 2010). Most of the 
wall glycoproteins are attached through a glycosylphophatidyl inositol (GPI) remnant to 
β(1,3)-D-glucan or chitin, via a β(1,6)-glucan linker. Other wall glycoproteins are 
directly covalently attached to β(1,3)-D-glucan (Klis et al., 2006). The wall 
glycoproteins contribute to the preservation of the cellular shape, participating in 
adhesion processes, transmitting signals to cytoplasm, and remodeling the components 
of the wall (Latge, 2007). 
 
5. Inhibitors of cell wall biosynthesis 
 
 As described above, the cell wall structure and rigidity depend on the layering 
and interlinking of (1,3)-glucan, (1,6)-glucan, chitin, α(1,3)-glucan and 
mannoproteins. Because the cell wall is absent in mammalian cells, its polysaccharides 
are attractive targets for the discovery and development of antifungal drugs. However, 
the types of polysaccharides, their extent and the linkages between them are quite 
variable across the fungal kingdom, and can change during the different growth phases. 
Therefore, the use of inhibitors of the synthesis of a specific wall component might 
result in different effects depending on the fungus or its stage of growth. 
 
5.1. Inhibitors of the (1,3)-glucan synthase (GS) 
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 To date, the GS is the only component of the cell wall synthesis machinery that 
has successfully led to the development and commercialization of new drugs on the 
market. In 2001, the Merck inhibitor of the GS caspofungin (Cancidas®, Merck, Sharp 
and Dhome, MSD) was approved for clinical use. Since then, antifungal drugs that 
inhibit the GS have extensively been used in clinic. The collection of marketed 
echinocandins also includes micafungin (Mycamine®, Astellas Pharma) and 
anidulafungin (Eraxis® or Ecalta®, Pfizer), which were approved for the treatment of 
invasive candidiasis and aspergillosis in 2005 and 2006-7, respectively (Sable et al., 
2008, Walsh et al., 2008, Chapman et al., 2008). Their structures are shown in figure 3. 
Additional members of this general class of GS inhibitors have emerged as preclinical 
candidates over the years, including papulacandins (Ciba-Geygy, Novartis), aerothricin 
analogs (Chugai Pharmaceutical and Basilea Pharmaceutica), cryptocandins (HMV 
Corporation), and other analogs (MSD, Astellas Pharma and Eli Lilly) (Hector and 
Bierer, 2011). However, this class of antifungals displays limitations as the lack of oral 
formulations, restricting them to parenteral formulations, and their semi-synthesis based 
on fermentation products. In addition, these compounds have a limited spectrum of 
activity showing no activity against, for example, C. neoformans. New -glucan 
inhibitors with a broad spectrum activity against the main fungal pathogens, some of 
them with oral bioavailability, have started to emerge (Hector and Bierer, 2011). 
 
5.1.1 Mode of action 
 
 The primary mode of action of this class of antifungals is the obstruction of the 
biosynthesis of the fungal cell wall by inhibiting the GS enzyme (Douglas et al., 1994b, 
Pérez et al., 1981, Yamaguchi et al., 1985), but little is known about their mechanisms 
of action. Inhibitors of β(1,3)-glucan synthesis also have secondary effects on other 
components of the cell, including a decrease in the ergosterol and lanosterol content and 
an increase in the chitin content of the cell wall (Pfaller et al., 1989). Echinocandins 
bind non-competitively to the catalytic subunit of GS. The inhibition of β(1,3)-glucan 
synthesis requires the uptake of echinocandins by sensitive cells. At low concentrations 
(<1 mg/ml), a high-affinity facilitated-diffusion transporter mediates the uptake of 
caspofungin, a semisynthetic pneumocandin B0 derivative (see below) in Candida 
albicans. At higher concentrations, nonspecific uptake can also progress (Paderu et al., 
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2004). The specificity of this class of antifungals for β(1,3)-glucan synthesis was 
demonstrated by the observation that echinocandins were ineffective in inhibiting chitin 
or mannan synthesis (Pérez et al., 1981). Substantial work has gone into the mechanistic 
understanding where echinocandins bind to the GS, but this question still remain 
obscure, largely because a membrane-associated protein is involved (Denning, 2003).  
 
 In yeasts, inhibitors of the GS increase the osmotic sensitivity of the cells and 
cause cell lysis; however resistant mutants with different behaviors against distinct 
antifungals compounds have been described, suggesting specific modes of action 
against the GS within this antifungal class (Martins et al., 2011). Only some S. 
cerevisiae and S. pombe mutants have been identified as resistant to the glycolipid 
papulacandin (Castro et al., 1995, Ribas et al., 1991b), in each case defining a single 
gene called pbr1, later found to be allelic to FKS1 and bgs4+, respectively. In S. pombe, 
wild type and the resistant mutant strains pbr1-8 and pbr1-6, display differences both in 
vivo and in vitro between papulacandin, enfumafungin and echinocandins (Martins et 
al., 2011). In S. pombe wild type cells, papulacandin and enfumafungin produce 
generalized cell lysis, while echinocandins are different; the lysis of wild type cells is 
incomplete, and the surviving cells become rounded and maintain a residual cell 
growth. Besides, whereas pbr1-8 and pbr1-6 are highly resistant to papulacandin and 
enfumafungin, they exhibit opposite behaviors with regard to aculeacin; pbr1-8 is 
highly resistant and pbr1-6 is sensitive (Martins et al., 2011). No GS activation by GS 
inhibitors has been reported, except for papulacandin in S. cerevisiae wild type GS and 
for enfumafungin, pneumocandin and caspofungin in S. pombe pbr1-8 GS (Kang et al., 
1986, Martins et al., 2011). In the case of S. cerevisiae, the drug activation affects the 
wild type GS and is dependent on low substrate concentrations. It is possible that some 
mutations, such as that S. pombe pbr1-8 GS, in the presence of an antifungal could 
mimic the proposed preferential binding of substrate to the active form of the enzyme. 
Caspofungin displays special properties as regards the in vitro GS activity, with an 
inhibitory concentration lower than that of other drugs, except papulacandin, and with 
two previously unreported inhibitory effects of high and low affinity (Figure 4), 
suggesting the presence of two GS interaction sites with caspofungin (Martins et al., 
2011). 
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 It is clear that the target to which these antifungals bind is the catalytic subunit 
of the GS, but their inhibitory effects on (1,3)-glucan synthesis do not necessarily 
would involve the catalytic subunit itself, nor is it clear whether their binding site on GS 
catalytic subunit is external or internal to the plasma membrane (Odds et al., 2003). For 
example, it has recently been suggested that the acyl side chain of the echinocandins 
may interact with the plasma membrane (Chen et al., 2011). 
 
5.1.2. Echinocandins 
 
 The commonly known as echinocandins (variously called lipopeptides, cyclic 
hexapeptides, pneumocandins, etc.) is a class of antifungals that specifically target the 
GS enzyme. Echinocandins (Figure 3) are large lipopeptide molecules, produced by 
fungi as secondary metabolites. The first echinocandin-type antimycotics, aculeacin A 
and echinocandin B, were isolated independently by random screenings in the 1970s. A 
modified form of echinocandin B, cilofungin, was developed to clinical use, but was 
abandoned when its formulation showed toxicity to patients in the trials. All the 
echinocandin derivatives in clinical use or development are amphiphilic cyclic 
hexapeptides with an N-linked acyl lipid side-chain (Denning, 2003, Kurtz and Rex, 
2001, Odds et al., 2003). The three echinocandins approved for clinic use (caspofungin, 
micafungin and anidulafungin) exhibit linear pharmacokinetics, are highly protein 
bound (97%–99%) and are not dialyzable. The echinocandins present some advantages 
which make them useful when used as additional antifungal treatment. Among common 
fungal pathogens, only C. neoformans is excluded from the echinocandins spectrum; but 
they also lack activity against emerging pathogens, such as Fusarium spp. and 
Scedosporium spp. However, they are active against Pneumocystis jiroveci (Odds et al., 
2003). Besides, echinocandins display an improved hepatic and renal safety profile 
compared with those of the azoles and polyenes, and decreased cytochrome-mediated 
drug interactions compared with those of the azoles (Walker et al., 2011). However, the 
main disadvantage of available echinocandins is that all of them have limited oral 
bioavailability, and therefore must be administered by intravenous infusion (Emri et al., 
2013, Sable et al., 2008).  
 
5.1.2.1 Caspofungin  
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 In 2001 Caspofungin (Cancidas®) was the first cell wall antifungal, 
commercialized by MSD and approved for clinical use in both the United States and the 
European Union. Caspofungin is used as salvage therapy for invasive aspergillosis. 
Caspofungin is a semisynthetic echinocandin derived from pneumocandin B
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0 via 
chemical modification of the hexapeptide scaffold (Figure 3). Pneumocandins are 
natural products derived from the fermentation of the fungus Glarea lozoyensis. The 
introduction of additional amino groups in the peptide ring of pneumocandin B0 
increased the solubility of the molecule and the potency against fungal pathogens by 
two orders of magnitude. The caspofungin group has lower rates of nephrotoxicity, 
infusion-related events, and drug-related adverse events (Denning, 2003, Emri et al., 
2013, Sable et al., 2008, Vicente et al., 2003). 
 
5.1.2.2 Micafungin  
 
 Micafungin (Mycamine®) was commercialized by Astellas Pharma and 
approved for clinical use in the United States and the European Union in 2005. It is a 
semisynthetic echinocandin produced from the echinocandin B FR901379 via 
substitution of the fatty acid side chain (Figure 3). Micafungin was approved for the 
treatment of esophageal candidiasis and for the prevention of Candida infections in 
patients undergoing hematopoietic stem cells transplantation. Micafungin is shown to be 
superior to fluconazole when given as prophylaxis in stem cell transplantation, and 
show less drug interactions than caspofungin (Denning, 2003, Odds et al., 2003, Sable 
et al., 2008). 
 
 
5.1.2.3 Anidulafungin 
 
 Anidulafungin was commercialized by Pfizer and approved for clinical use in 
the United States in 2006 (Eraxis®) and in the European Union in 2007 (Ecalta®). It is a 
semisynthetic echinocandin produced from echinocandin B, via substitution of the fatty 
acid side chain (Figure 3). It is used against esophageal candidiasis, candidemia, and 
other Candida infections (intra-abdominal abscess and peritonitis). It is highly active in 
vitro against a wide range of Candida spp, including those that are resistant to azoles 
(C. krusei), amphotericin B (C. lusitaniae) or other echinocandins (C. parapsilosis), and 
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also against species of Aspergillus spp. (Denning, 2003, Emri et al., 2013, Kathiravan et 
al., 2012, Sable et al., 2008). 
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5.1.2.4 Echinocandin B derivatives 
 
 A series of cyclohexapeptide echinocandin semi-synthetic derivatives and 
formulations are the subject of several patents. In one of these patents it is claimed that 
the natural products echinocandin B, aculeacin, pneumocandin A0, pneumocandin B0, 
pneumocandin C0 and cilofungin may also be used as synthetic starting points. Activity 
against several Candida, Aspergillus and Cryptococcus strains is mentioned for the 
described compounds, but biological data are not provided. Although not shown, it is 
stated that some of the echinocandin B derivatives present good activity in vitro against 
the GS of C. albicans and A. fumigatus (Hector and Bierer, 2011). 
 
5.1.3 Enfumafungin and MK-3118 
 
 Enfumafungin is a hemiacetal triterpene glycoside (Figure 3) that was originally 
isolated by the fermentation of Hormonema sp. It exists as a mixture of two 
interconverting forms at the hemiacetal state, and it was determined that the natural 
product specifically inhibits the GS (Pelaez et al., 2000, Onishi et al., 2000, Martins et 
al., 2011). MK-3118 (Figure 3) is an orally active, semisynthetic derivative of 
enfumafungin with in vitro and in vivo activity against Candida spp and Aspergillus 
spp. MK-3118 and other derivatives of enfumafungin are potent inhibitors of fungal GS, 
yet these compounds are structurally distinct from the echinocandins. The sites of 
mutations in Fks GS that are associated with resistance to the echinocandins are in some 
cases distinctly different from those causing decreased susceptibility to the 
enfumafungin derivatives. MK-3118 displays in vitro an excellent activity against wild 
type Candida spp, and wild type and itraconazole-resistant strains of Aspergillus 
(Hector and Bierer, 2011, Pfaller et al., 2013b, Pfaller et al., 2013a, Walker et al., 2011). 
In vivo, the preclinical results demonstrate a comparable level of activity for MK-3118 
against Candida spp. compared with caspofungin, while mouse efficacy results for 
aspergillosis suggest a somewhat inferior response compared with caspofungin. 
Importantly, the demonstration of oral bioavailability with MK-3118 suggests that 
formulations of this drug may be dosed either orally or parenterally, providing a much 
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needed flexibility to the class of GS inhibitors as antifungal agents (Hector and Bierer, 
2011). 
 
5.1.4 Papulacandins 
 
 The glycolipids papulacandins (Figure 3) are a series of naturally occurring 
antifungal agents containing a benzannulated spiroketal unit, which has been the 
signature of a wide series of bioactive natural products and has inspired ample synthetic 
activity. The papulacandins A–E were isolated from the fermentation broths of 
Papularia sphaerosperma (Traxler et al., 1977, van der Kaaden et al., 2012). They 
block the synthesis of β(1,3)-glucan by inhibition of GS (Baguley et al., 1979, Pérez et 
al., 1981, Varona et al., 1983). Interestingly, it has been observed a general decline in 
the inhibition of GS as the concentration of the substrate UDP-glucose is decreased. 
Surprisingly, at very low concentrations of UDP-glucose, papulacandin B even acted as 
a stimulator, suggesting that UDP-glucose might act as an allosteric ligand, shifting the 
enzyme from one conformation to another once its concentration increases. Within the 
range of substrate concentrations in which papulacandin B is inhibitory, the inhibition 
appears to be of the mixed type, although very close to non-competitive (Kang et al., 
1986, Pérez et al., 1981). Papulacandins display a very high specific activity against 
several yeasts, but they are largely inactive against filamentous fungi, bacteria and 
protozoa (Traxler et al., 1977). Direct comparison (Figure 4 and not shown) between 
glycolipids (papulacandin B), echinocandins (pneumocandin, caspofungin and 
aculeacin) and acidic terpenoids (enfumafungin) has shown that papulacandin B 
inhibitory effect of GS activity is superior in several orders of magnitude to that of the 
other antifungals (Martins et al., 2011). Several new compounds structurally related to 
papulacandins have been isolated (van der Kaaden et al., 2012). Their structures diverge 
with respect to the two partially unsaturated acyl chains on the sugars. Drastic changes 
in these tails or the lack of one of the tails severely reduce their activity compared with 
the most active papulacandin B (van der Kaaden et al., 2012). Due to their limited 
potency in animal models, neither papulacandin B nor any of its derivatives have been 
developed as GS inhibitory drugs for clinical use (Vicente et al., 2003). 
 
5.1.5. Pyridazinone derivatives  
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 Since the echinocandins used in clinic are delivered only parenterally, there is a 
significant interest in identifying new and unrelated GS inhibitors. A search for 
antifungal bioactivities combined with mechanism-of-action studies identified a new 
class of piperazinyl-pyridazinones that target the GS. The generic form of pyridazinone 
compounds that inhibit the GS is shown in figure 3 (Hector and Bierer, 2011). These 
compounds exhibit in vitro activity comparable, and in some cases superior, to that of 
echinocandins (Walker et al., 2011, Hector and Bierer, 2011, Butts and Krysan, 2012). 
The pyridazinone compounds inhibit GS in vitro, with a strong correspondence between 
enzyme inhibition and in vitro antifungal activity. Moreover, the compounds cause cell 
lysis and release of cytoplasmic contents as other GS inhibitors. Importantly, this novel 
class of small-molecule GS inhibitors present oral efficacy in a murine model of 
disseminated C. glabrata infection. The oral availability of these pyridazinone 
derivatives distinguishes them from the echinocandins (Walker et al., 2011). 
 
5.1.6 Other inhibitors of the GS 
 
 Besides echinocandins, other cyclic peptides have been described as inhibitors of 
(1,3)-glucan synthesis (Vicente et al., 2003, Hector and Bierer, 2011). The 
echinocandin-related Cryptocandin has an inhibitory activity against C. albicans and 
Trychophyton spp (Strobel et al., 1999). Arborcandins are other antifungal agents 
described as GS inhibitors, containing a 10-amino-acid ring and two lipophilic tails 
(Ohyama et al., 2000). Similarly, Aerothricin3/FR901469 is a macrocyclic 
lipopeptidolactone composed of 12 amino acids and a 3-hydroxypalmitoyl moiety with 
GS inhibitory activity (Fujie et al., 2001, Kondoh et al., 2002). The piperazine propanol 
derivative GSI578 [(2,6-Difluoro-phenyl)-carbamic acid 3-(4-benzothiazol-2-yl-
piperazine-1-yl)-propyl ester] is a synthetic antifungal drug described as GS inhibitor 
(Kondoh et al., 2005). Clavariopsins, cyclic depsipeptides lacking a long lipophilic 
radical, have also been described as inhibitors of glucan synthesis (Kaida et al., 2001). 
New chlorogenic, quinic and caffeic acid derivatives that were coupled with an H2N-
orn-4-(octyloxy) aniline group have been described to display antifungal activities by 
partial inhibition of GS (Ma et al., 2010). Additionally, several new synthetized 4-aryl-
4-N-arylamine-1-butene compounds display antifungal properties and specific 
inhibitory activity on the GS (Urbina et al., 2000). 
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 Nowadays, a significant problem of the public health is the rising prevalence of 
resistance to antimicrobial agents among important human pathogens, which is severely 
restricting the availability of treatments for common infections (Ben-Ami and 
Kontoyiannis, 2012). Although resistance to echinocandins and other GS inhibitors is 
still relatively uncommon, it is increasingly encountered; moreover, the clinical 
susceptibility breakpoints for echinocandins result in the inclusion of a greater 
proportion of clinical isolates in the resistant category (Pfaller et al., 2011a, Ben-Ami 
and Kontoyiannis, 2012). 
 
 Fungal resistance to GS inhibitors is clearly associated with mutations grouped 
in conserved short regions (hot spots) of the Fks proteins (Figure 5B), indicating that 
this resistance mechanism is well conserved in fungi (Perlin, 2007, Rocha et al., 2007, 
Walker et al., 2010). In addition, some fungi are naturally resistant to echinocandins, as 
they contain natural substitutions in the conserved Fks hot spot regions that are 
determinants of their resistance (Katiyar and Edlind, 2009, Perlin, 2007, Walker et al., 
2010). FKS hotspot mutations which confer resistance to echinocandin are frequently 
associated with changes in cell wall thickness, attributed to increased cell wall chitin 
content due to upregulation of chitin synthesis as a result of activation of cell wall 
salvage pathways (Walker et al., 2008, Ben-Ami and Kontoyiannis, 2012). In these 
cases, the combination of echinocandins with chitin synthase inhibitors (see below) 
avoids the increase of cell wall chitin, preventing the growth of echinocandin-resistant 
strains that contain FKS1 hot spot mutations (Walker et al., 2008, Munro, 2013). 
 
 Another resistance effect associated to just activation of compensatory 
mechanisms from the cell integrity and calcineurin pathways is the termed paradoxical 
growth effect, or Eagle effect, described for Candida spp. This paradoxical effect 
consists of an in vivo attenuation of growth inhibition at drug concentrations above the 
inhibitory concentration. The result is growth inhibition followed by a resumption of 
growth at higher antifungal concentrations and a new inhibitory effect when the drug 
concentration increases. In this case, the resistance is not due to Fks hot spot mutations 
and therefore, it is only observed on the in vivo cell growth but not on the in vitro GS 
activity (Fleischhacker et al., 2008, Wiederhold, 2007). 
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 Clearly, a weak point in all the (1,3)-glucan synthesis inhibitors discovered or 
developed up to date is their lack of activity against C. neoformans. This is something 
intriguing since the FKS1 homologue gene of this fungus has been shown to be 
essential, leading to the proposal that its GS enzyme could be relatively resistant to the 
action of echinocandins and the rest of the (1,3)-glucan synthesis inhibitors. However, 
the in vitro GS assays have demonstrated that the GS from C. neoformans is in fact very 
sensitive to caspofungin and cilofungin (Maligie and Selitrennikoff, 2005), indicating 
that C. neoformans is resistant to echinocandins through other mechanisms. 
 
 S. pombe is a good model for in vivo and in vitro studies of the resistance 
mechanisms to GS inhibitors (see above). It is interesting that exclusively some S. 
cerevisiae and S. pombe mutants display resistance or have been found resistant to 
papulacandin (see above and Figure 5A). Although S. pombe vegetative cells contain 
three essential Bgs subunits which all contain in their hot spots the conserved aminoacid 
sequences associated to natural antifungal sensitivity, the antifungal resistance is only 
associated with Bgs4 hot spot mutations, suggesting that Bgs1 and Bgs3 are natural 
intrinsic resistant subunits (Figure 5B). The analysis of mutants resistant to 
papulacandin expanded the resistance hot spot 1 to 13 aminoacids and defined a new 
resistance hot spot 1-2 (Martins et al., 2011). These new sites, which are important for 
resistance and interaction with antifungals, should help to understand the mechanism of 
action of antifungals, and the resistance mechanism to GS inhibitors of the Fks proteins. 
 
5.2 New inhibitors of (1,6)-glucan synthesis 
 
 C. neoformans is an encapsulated pathogenic yeast that is responsible for 
pulmonary infections and fatal meningoencephalitis in humans. Disseminated 
cryptococcosis is one of the main causes of death among immunocompromised patients, 
while cryptococcal pneumonia is one of most common manifestation of cryptococcosis 
in AIDS patients. As stated above, to date all the described or developed (1,3)-glucan 
synthesis inhibitors are ineffective against C. neoformans. Since its GS is very sensitive 
to echinocandins (Maligie and Selitrennikoff, 2005), one hypothesis for the resistance of 
C. neoformans is that the pathogen capsule could inhibit the access of the drug to the 
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transmembrane GS. However, limitation of accessibility is an unlikely explanation since 
the minimal inhibitory concentrations of echinocandins for acapsular strains are similar 
to those for encapsulated strains (Feldmesser et al., 2000). Other theoretical explanation 
may be that echinocandins do not inhibit (1,6)-glucan synthesis, which seems to be the 
main glucan in C. neoformans wall (Free, 2013, Feldmesser et al., 2000). Besides C. 
neoformans, in other fungal species (Candida parapsilosis, Candida guilliermondii, 
Neurospora crassa, Fusarium graminearum, Fusarium solani, Fusarium verticilliodes 
and Magnaporthe grisea) it has been found that their wild type Fks1 sequence contains 
natural substitutions in their hot spot region that are determinants of their resistance 
(Walker et al., 2010). Therefore, the search, design and development of novel drugs that 
specifically target the synthesis of (1,6)-glucan might be essential to bypass the 
resistance of C. neoformans and other fungi, which are intrinsic resistant to GS 
inhibitors. Besides the importance of the (1,6)-glucan as new target in those resistant 
species, this cell wall polymer is essential for virulence in C. albicans (Herrero et al., 
2004, Umeyama et al., 2006), representing an additional target for antifungals. 
 
 Recently several works and a patent have described new bicyclic heteroaryl ring 
derivatives as inhibitors of (1,6)-glucan synthesis (Figure 3 shows the generic bicyclic 
heteroaryl ring), which have been reported to have in vitro and in vivo activity against a 
range of Candida spp (Kitamura et al., 2009a, Kitamura et al., 2009b, Kitamura et al., 
2010, Takeshita et al., 2010, Hector and Bierer, 2011). Unfortunately, like the (1,3)-
glucan synthesis inhibitors reported to date, the (1,6)-glucan synthesis inhibitors have 
little or no in vitro activity against C. neoformans. As stated above, most of wall 
glycoproteins are bound to the cell wall through a glycosylphophatidyl inositol (GPI) 
residue via a branched β(1,6)-glucan linker (Figure 1). Recently, the novel compound 
E1210, orally active isoxazole-based inhibitor of glycosylphosphatidylinositol (GPI)-
linked protein biosynthesis, has been shown to have a good activity against C. 
neoformans, as well as a wide range of medically relevant yeasts and molds (Pfaller et 
al., 2011c, Pfaller et al., 2011b, Miyazaki et al., 2011). 
 
5.3 Chitin synthase (CS) inhibitors as a target for antifungal therapy 
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 Chitin is one of the main wall polysaccharides, which is vital for the 
maintenance of cell wall structure and integrity. Therefore, inhibition of chitin synthesis 
has been proposed as an attractive target for antifungal treatments. Differently from GS, 
no CS inhibitor has ever been developed into drug for clinical use (Munro, 2013). 
Existing CS inhibitors such as peptidyl nucleoside antibiotics polyoxins (or 
nikkomycins) are more potent and specific against class I enzymes, and less effective 
against the other classes. Their structures imitate the structure of the Chs substrate and 
thus, they act as competitive inhibitors (Gaughran et al., 1994, Munro, 2013, Lenardon 
et al., 2010). The finding that CHS1 is essential for the viability of C. albicans (Munro 
et al., 2001) pointed to the search of novel inhibitors of the class II CS. The compound 
RO-09-3143 inhibits specifically to Chs1, and it is only fungicide to C. albicans in the 
absence of Chs2 (Sudoh et al., 2000), suggesting the existence of compensatory 
mechanisms between the different CS enzymes. Supporting this observation, C. 
albicans yeast cells harboring chs1Δ deletion (absence of Chs1) were able to grow 
when treated with Ca
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 and the chitin-interfering fluorochrome Calcofluor white, due to 
an increase of the chitin content and the synthesis of a new remedial septum (Walker et 
al., 2008). In conditions of stress or when the integrity of the cell wall is affected, this 
structure is reinforced by increasing the synthesis of chitin, either in S. cerevisiae or in 
C. albicans (Lenardon et al., 2010). In addition, C. albicans fks1 mutants display 
increased cell wall thickness, which is attributed to higher cell wall chitin content. 
Something similar is observed when fungi are grown in the presence of sub-lethal 
concentrations of echinocandins (Ben-Ami and Kontoyiannis, 2012).  
 
 Synthesis of chitin-rich cell walls results from activation of cell wall salvage 
pathways, including the high osmolarity mitogen activated protein kinase, the protein 
kinase C and the Ca2+/calcineurin pathways. These compensatory mechanisms are 
though to reduce the sensitivity of C. albicans to echinocandins. Therefore, the 
combined treatment of echinocandins with CS inhibitors is more effective than 
individual drug treatments (Walker et al., 2008, Munro, 2013, Lenardon et al., 2010). In 
addition, the treatment with antagonists of the calcineurin pathway, which regulates 
chitin synthesis in C. albicans and A. fumigatus, as well as the response to echinocandin 
drugs, have shown a synergistic effect when combined with echinocandins and CS 
inhibitors (Fortwendel et al., 2009, Hill et al., 2013, Lamoth et al., 2012, Lenardon et 
al., 2010, Munro, 2013, Walker et al., 2008, Wiederhold et al., 2005).  
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6. Perspective 
 
 In the past decade there have been important advances in antifungal therapy. 
Several new antifungal agents have received authorization for clinical use in the United 
States and European Union. Sadly, with some exceptions against certain fungi, available 
antifungal compounds are fungistatic rather than fungicidal; and therefore, treatments 
for life-threatening mycoses require prolonged periods of time, conducing to the 
emergence of drugs resistance in fungal pathogens, which is compromising the 
efficiency of the available antifungal drugs. The combined treatment of inhibitors of the 
main cell wall components, together with azole antifungals and antagonists of pathways 
involved in mechanisms of antifungal resistance, is a powerful strategy to abrogate 
fungal resistance and combat invasive fungal infections. In addition to orally available 
azole compounds, the new formulations with oral bioavailability, the broad array of 
natural, semi-synthetic and synthetic compounds that have shown an specific activity 
against (1,3)-glucan synthesis, together with the new inhibitors of (1,6)-glucan 
synthesis, will supply more powerful increased activity and spectrum of activity against 
most of the pathogenic fungi. Unfortunately, with the exception of the three closely 
related echinocandins now on the market, no new antifungals have been develop to 
advance clinical testing. However, the diversity of antifungal classes with activity 
against -glucans reviewed in the present chapter, plus the prospect of oral 
bioavailability, will open new strategies to develop novel, safe and more effective drugs 
as additional treatments and managements of life-threatening mycoses.  
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FIGURE LEGENDS 
 
Figure 1. Sites of action of antifungal agents. Illustration of the sites of action of 
currently available antifungals. A. Echinocandins inhibit the (1,3)-glucan synthase 
(GS) and the formation of the (1,3)-glucan of the fungal cell wall. It is shown a 
schematic representation of the synthesis and organization of the -glucans. The 
synthesis of linear (1,3)-glucan chains starts in the plasma membrane by the GS. Then 
cell wall transglycosidases form branched (1,3)(1,6)-glucan bound to chitin via 
(1,4) linkages. Proteins are covalently attached to (1,3)(1,6)-glucans through the 
GPI remnant or through a glutamine residue following a transglutaminase reaction. B. 
Polyene antifungals bind to fungal ergosterol, disturbing the plasma membrane 
function. C. Azole agents target the biosynthesis of ergosterol at the endoplasmic 
reticulum, leading to an altered plasma membrane depleted of ergosterol. D. 
Griseofulvin presumably binds to tubulin, thus interfering with the assembly of 
microtubules and inhibiting the nuclear mitosis. E. 5-Fluorocytosine or Flucytosine 
interferes with DNA and RNA synthesis. F. Sordarins block the fungal translation thus 
interfering with protein synthesis. 
 
Figure 2. Structure and composition of fungal cell wall. The upper panel shows a 
cartoon of the organization and composition of the main fungal cell wall layers with the 
cell wall synthases embedded in the plasma membrane. Transmission electron micrographs 
of a fission yeast cell and a detail of the cell wall are presented in the lower panel. 
 
Figure 3. Chemical structures of the main inhibitors of cell wall -glucan 
biosynthesis. Echinocandins (pneumocandin, caspofungin, micafungin and anidulafungin), 
papulacandins (papulacandin B), acidic terpenoids (enfumafungin and MK-3118) and 
pyridazinone derivatives inhibit the GS activity and thus the synthesis of (1,3)-glucan. 
Derivatives of bicyclic heteroaryl ring inhibit the synthesis of (1,6)-glucan. For simplicity 
the generic forms of pyridazinone and the bicyclic heteroaryl ring are shown. See the text 
for more details.  
 
Figure 4. Differential inhibitory effect of pneumocandin B0, caspofungin and 
papulacandin B on the in vitro GS activity of Schizosaccharomyces pombe wild type 
cell extracts. Caspofungin exhibits a higher inhibitory capacity than pneumocandin and 
lower than papulacandin B. Besides caspofungin displays a dual inhibitory effect, at low 
and high concentrations (1st and 3rd sections marked by dotted lines), separated by a 
plateau of a 100-fold drug increase with no increase in inhibition (2nd section marked 
by dotted lines). Adapted from Martins et al., 2011. 
 
Figure 5. Mapping of the Fks hot spots that confer fungal resistance to GS 
inhibitors. A. Hydropathy profile of Bgs4. The two predicted transmembrane (TM) 
regions and the sites where Bgs4pbr1-8-E700V and Bgs4pbr1-6-W760S are located in the 
hot spot 1 in the first transmembrane region and the sites where the hot spot 2 is located 
in the second transmembrane region are shown. B. Sequence alignment of two 
conserved regions of 70 and 24 amino acids of Bgs1, Bgs2, Bgs3, and Bgs4 from S. 
pombe, Fks1 and Fks2 from Saccharomyces cerevisiae (Sc), Gsc1 (Fks1) from Candida 
albicans (Ca), and Fks1 and Fks2 from Candida glabrata (Cg). The amino acid 
mutations described to confer resistance to echinocandins in S. cerevisiae, C. albicans, 
and C. glabrata, defining two resistance hot spot 1 and hot spot 2 of 9 and 4 aminoacids 
respectively, are shown. The Bgs4pbr1-8 mutation is located 4 amino acids N-terminal 
from hot spot 1, increasing the cluster to a 13-amino acid hot spot 1-1 of resistance to 
papulacandin, enfumafungin, and echinocandins. The Bgs4pbr1-6 change is located 48 
amino acids C-terminal from hot spot 1-1, defining a novel hot spot 1-2 of resistance to 
the three antifungal families. Adapted from Martins et al., 2011. 
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